Razorfish: Mayer De...
Health Care: Drugs
Santarus Inc. (SNTS: NASDAQ)
$21.80 -0.30 | -1.36%
05/21/13 - 12:20 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 49.77M | 54.24M | 56.69M | 86.13M |
| Receivables | 31.02M | 20.27M | 7.16M | 16.25M |
| Inventories | 9.90M | 5.13M | 3.02M | 5.34M |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 142.34M | 87.72M | 77.06M | 119.33M |
| Property, Plant & Equipment, Gross | 3.84M | 3.22M | 3.24M | 3.03M |
| Accumulated Depreciation & Depletion | 2.90M | 2.65M | 2.47M | 2.16M |
| Property, Plant & Equipment, Net | 945.00K | 578.00K | 774.00K | 875.00K |
| Intangibles | 16.25M | 21.79M | 13.98M | 9.75M |
| Other Non-Current Assets | 1.30M | 1.05M | 1.31M | 1.41M |
| Total Non-Current Assets | 21.41M | 26.33M | 18.97M | 12.03M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 163.75M | 114.05M | 96.04M | 131.36M |
| Accounts Payable | 6.87M | 4.55M | 29.47M | 58.68M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 21.52M | 14.48M | 13.45M | 12.85M |
| Total Current Liabilities | 66.40M | 49.31M | 42.92M | 71.77M |
| Long Term Debt | 9.88M | 10.00M | 10.00M | 10.00M |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 4.52M | 4.66M | 5.13M | 2.68M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 14.40M | 14.66M | 15.13M | 12.68M |
| Total Liabilities | 80.80M | 63.96M | 58.05M | 84.44M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 82.95M | 50.09M | 37.98M | 46.92M |
| Common Par | 6.00K | 6.00K | 6.00K | 6.00K |
| Additional Paid In Capital | 368.59M | 354.29M | 346.85M | 337.31M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -285.65M | -304.21M | -308.88M | -290.40M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 3.00K | 0.00 | 0.00 | -1.00K |
| Total Capitalization | 92.83M | 60.09M | 47.98M | 56.92M |
| Total Equity | 82.95M | 50.09M | 37.98M | 46.92M |
| Total Liabilities & Stock Equity | 163.75M | 114.05M | 96.04M | 131.36M |
| Total Common Shares Outstanding | 63.58M | 61.11M | 60.01M | 58.34M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 62.70M | 60.53M | 58.73M | 57.99M |
| Diluted Weighted Shares Outstanding | 69.15M | 62.81M | 58.73M | 59.67M |
| Number of Employees | 290 | 240 | 223 | 335 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with SNTS
- Portfolio NameUser Type
- UserWatch
- ContributorStocks Under-$10 Setting Up...
- ContributorDrugs Facing FDA Approval i...
- ContributorBreakout Stocks Of The Week...
- UserRogers BioMed
- ContributorStocks At New 52-Week Highs...
- UserJust Learning ao926
- UserJust Learning
- ContributorDollar Store
- Userbetterlatethannever
Latest SNTS Headlines from TheStreet
- Dow Closes at Record High 03.05.13 | 04:03 pm
- Cramer's 'Mad Money' Recap: The Bullish Facts 01.17.13 | 08:01 pm
- 5 Stocks Insiders are Buying This Week 12.26.12 | 12:12 pm
- Top Insider Trades: LMCA, ST, SNTS, BEAV 12.20.12 | 01:12 pm
- Stocks Under $5: Discount Drug Name
11.29.12 | 06:11 am - 5 Under-$10 Stocks Set to Trade Higher in November 11.08.12 | 01:11 pm
- Santarus Inc. Stock Upgraded (SNTS) 08.27.12 | 05:08 am
- Santarus' CEO Discusses Q2 2012 Results - Earnings Call Transcript 08.07.12 | 09:08 pm
- Santarus Reaches New 52-Week High (SNTS) 06.12.12 | 04:06 pm
- Santarus Stock Falls On Unusually High Volume (SNTS) 05.30.12 | 04:05 pm
Press Releases for SNTS
- Santarus Announces Publication In Gut Of Results From UCERIS (budesonide) European Pivotal Clinical Study - Business Wire 03.18.13 | 07:03 am
- Santarus And VeroScience Announce Publication Of AACE Expert Panel Recommendations For CYCLOSET® (bromocriptine Mesylate) For The Management Of Type 2 Diabetes - Business Wire 03.06.13 | 07:03 am
- Santarus Reports Fourth Quarter And Full Year 2012 Financial Results - Business Wire 03.04.13 | 04:03 pm
- Santarus To Present At March Investment Conferences - Business Wire 02.27.13 | 07:02 am
- Santarus To Hold Fourth Quarter And Full Year 2012 Financial Results Conference Call On March 4 - Business Wire 02.19.13 | 07:02 am
- Santarus Announces Commercial Launch Of UCERIS (budesonide) Extended Release Tablets - Business Wire 02.14.13 | 07:02 am
- Santarus To Present At Leerink Swann Global Healthcare Conference - Business Wire 02.06.13 | 07:02 am
- Santarus And VeroScience Announce Publication Of Positive Data From Pivotal CYCLOSET® (bromocriptine Mesylate) Efficacy Study - Business Wire 01.23.13 | 07:01 am
- Santarus Receives FDA Approval Of UCERIS (Budesonide) For The Induction Of Remission In Patients With Active, Mild To Moderate Ulcerative Colitis - Business Wire 01.14.13 | 07:01 pm
- Santarus And VeroScience Announce Publication Of New Analysis Of CYCLOSET (bromocriptine Mesylate) Cardiovascular Data In The Journal Of The American Heart Association - Business Wire 11.13.12 | 07:11 am
Partner Headlines for SNTS
- FDA Panel Kills Sefelsa, Creates Buying Opportunity In Depomed Stock - Seeking Alpha 03.05.13 | 09:03 am
- Roth Capital's Henry Sees Upcoming FDA Panel For Depomed's Sefelsa As A Coin Flip - Seeking Alpha 03.01.13 | 05:03 pm
- Serada Approval Presents Big Upside To Depomed - Seeking Alpha 01.30.13 | 09:01 am
- Three Compelling Biopharma Stocks For 2013 - Seeking Alpha 12.26.12 | 09:12 am
- 5 BioPharmas To Watch For Wednesday, September 5 - Seeking Alpha 09.05.12 | 09:09 am
- Santarus - Momentum - Zacks 07.18.12 | 01:07 am
- Verizon and 2 Stocks BREAKING 52-Week Highs - Wall St. Cheat Sheet 06.13.12 | 12:06 pm
- Most Volatile Stocks on Earnings Report Days - Seeking Alpha 01.07.11 | 07:01 pm
- UPDATE 1-Santarus files for approval of anti-swelling drug - Reuters 12.28.10 | 09:12 am
- Santarus' Q3 Loss: The Rough Path to Recovery - Seeking Alpha 11.09.10 | 09:11 am
